Literature DB >> 26045829

Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.

Zong-Hua Shi1, Guang-Yong Shi2, Lin-Gang Liu1.   

Abstract

We conducted a perspective study to assess the association between ERCC1 and XPF polymorphisms and response to chemotherapy and clinical outcome of NSCLC receiving chemotherapy. Between May 2009 and May 2011, a prospective study was conducted on 240 NSCLC cases. Genotypes of ERCC1 (rs11615, rs3212986 and rs2298881) and XPF (rs2276465 and rs6498486) were performed by Polymerase Chain Reaction Restriction Fragment Length Polymorphism (PCR-RFLP) assay. By conditional logistic regression analysis, patients carrying AA genotype of ERCC1 rs11615 showed more CR+PR to chemotherapy when compared with GG genotype, and the adjusted OR (95% CI) was 2.73 (1.21-6.18). By Cox regression analysis, AA genotype of ERCC1 rs11615 was associated with longer overall survival of NSCLC, and the adjusted HR (95% CI) was 0.38 (0.14-0.96). In conclusion, our study found that ERCC1 rs11615 polymorphism can influence the chemotherapy response and overall survival of NSCLC patients receiving cisplatin-based chemotherapy.

Entities:  

Keywords:  ERCC1; XPF; clinical outcome; non-small cell lung cancer; polymorphism

Mesh：

Substances：

Year:  2015        PMID： 26045829      PMCID： PMC4440138     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN： 1936-2625


  23 in total

Review 1.  Pharmacogenomics: translating functional genomics into rational therapeutics.

Authors:  W E Evans; M V Relling
Journal:  Science       Date:  1999-10-15       Impact factor: 47.728

2.  Polymorphisms in ERCC1 gene could predict clinical outcome of platinum-based chemotherapy for non-small cell lung cancer patients.

Authors:  Xin Zhao; Zhiqiang Zhang; Yan Yuan; Xiaomei Yuan
Journal:  Tumour Biol       Date:  2014-05-24

Review 3.  Nucleotide excision repair gene ERCC1 19007T>C polymorphism contributes to lung cancer susceptibility: a meta-analysis.

Authors:  Fuyi Xie; Qi Sun; Shengjun Wu; Xinyou Xie; Zhiwei Liu
Journal:  Genet Test Mol Biomarkers       Date:  2014-07-22

4.  Association of DNA repair gene polymorphisms with response to chemotherapy and prognosis of gastric cancer.

Authors:  Z H Chen; L Wang; L P Luo
Journal:  Genet Mol Res       Date:  2014-09-12

5.  Gastrostomy in oropharyngeal cancer patients with ERCC4 (XPF) germline variants.

Authors:  David G Kornguth; Adam S Garden; Yuxin Zheng; Kristina R Dahlstrom; Qingyi Wei; Erich M Sturgis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

Review 6.  Unraveling DNA repair in human: molecular mechanisms and consequences of repair defect.

Authors:  N Tuteja; R Tuteja
Journal:  Crit Rev Biochem Mol Biol       Date:  2001       Impact factor: 8.250

Review 7.  Cisplatin in advanced cancer of the cervix: an update.

Authors:  D S Alberts; D Garcia; N Mason-Liddil
Journal:  Semin Oncol       Date:  1991-02       Impact factor: 4.929

8.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

9.  Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.

Authors:  K R Fareed; A Al-Attar; I N Soomro; P V Kaye; J Patel; D N Lobo; S L Parsons; S Madhusudan
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

10.  Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.

Authors:  Anderson T Wang; Blanka Sengerová; Emma Cattell; Takabumi Inagawa; Janet M Hartley; Konstantinos Kiakos; Nicola A Burgess-Brown; Lonnie P Swift; Jacqueline H Enzlin; Christopher J Schofield; Opher Gileadi; John A Hartley; Peter J McHugh
Journal:  Genes Dev       Date:  2011-09-01       Impact factor: 11.361
View more
  5 in total

Review 1.  Synonymous Variants: Necessary Nuance in Our Understanding of Cancer Drivers and Treatment Outcomes.

Authors:  Nayiri M Kaissarian; Douglas Meyer; Chava Kimchi-Sarfaty
Journal:  J Natl Cancer Inst       Date:  2022-08-08       Impact factor: 11.816

2.  Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.

Authors:  Juanmei Mo; Min Luo; Jiandong Cui; Shaozhang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis.

Authors:  Li-Ming Tan; Cheng-Feng Qiu; Tao Zhu; Yuan-Xiang Jin; Xi Li; Ji-Ye Yin; Wei Zhang; Hong-Hao Zhou; Zhao-Qian Liu
Journal:  Sci Rep       Date:  2017-07-17       Impact factor: 4.379

4.  XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation.

Authors:  Leisa Lopes-Aguiar; Ericka Francislaine Dias Costa; Guilherme Augusto Silva Nogueira; Tathiane Regine Penna Lima; Marília Berlofa Visacri; Eder Carvalho Pincinato; Luciane Calonga; Fernanda Viviane Mariano; Albina Messias de Almeida Milani Altemani; João Maurício Carrasco Altemani; Cláudia Malheiros Coutinho-Camillo; Maria Almerinda Vieira Fernandes Ribeiro Alves; Patrícia Moriel; Celso Dario Ramos; Carlos Takahiro Chone; Carmen Silvia Passos Lima
Journal:  Oncotarget       Date:  2017-03-07

5.  The ECCR1 rs11615, ERCC4 rs2276466, XPC rs2228000 and XPC rs2228001 polymorphisms increase the cervical cancer risk and aggressiveness in the Bangladeshi population.

Authors:  Shiba Das; Lutfur Naher; Tutun Das Aka; Md Abdul Aziz; Samia Shabnaz; Mohammad Shahriar; Mohammad Safiqul Islam
Journal:  Heliyon       Date:  2021-01-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.